OpGen (NASDAQ:OPGN) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of OpGen (NASDAQ:OPGN – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning.

OpGen Price Performance

OPGN opened at $0.70 on Tuesday. The firm has a 50 day moving average price of $1.10 and a 200 day moving average price of $0.98. The company has a market cap of $3.86 million, a PE ratio of -0.05 and a beta of -0.20. OpGen has a 1 year low of $0.55 and a 1 year high of $16.40. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.88 and a current ratio of 1.01.

OpGen (NASDAQ:OPGN – Get Rating) last issued its quarterly earnings data on Wednesday, March 29th. The medical research company reported ($1.90) earnings per share (EPS) for the quarter. The firm had revenue of $0.72 million during the quarter. OpGen had a negative net margin of 1,429.56% and a negative return on equity of 120.63%. Sell-side analysts expect that OpGen will post -3.83 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP bought a new position in OpGen in the 1st quarter worth approximately $49,000. Virtu Financial LLC bought a new position in OpGen in the first quarter valued at about $64,000. FNY Investment Advisers LLC acquired a new position in OpGen in the fourth quarter valued at about $232,000. Citadel Advisors LLC lifted its stake in OpGen by 571.0% in the third quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after buying an additional 85,754 shares during the period. Finally, HRT Financial LP acquired a new position in OpGen in the fourth quarter valued at about $26,000. 16.36% of the stock is owned by institutional investors and hedge funds.

OpGen Company Profile

(Get Rating)

OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm’s also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms.